zPREDICTA

Acquired

Patient-derived 3D tissue reconstruction models for preclinical…

San Jose, United States · Founded 2014 · $220K raised

Employees
1–10
Founded
2014
Total Funding
$220K
Last Round
$120K SeedAug 2015
Rounds
2

About

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications.

Summary

zPREDICTA is a Healthcare company based in San Jose, United States, founded in 2014. It has raised $220K in total across 2 rounds, most recently a $120K Seed round in Aug 2015. Investors include Y Combinator, Propel(X) and Great Oaks VC.

Tech & App Stack

4 technologies & apps tracked

Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.

Sign up to view funding chart

Create a free account to see funding visualizations and detailed round data.

Funding History

SeedSeed RoundAug 2015
$100K

Sign up to see all 2 rounds

Full funding history, per-round amounts, and investor participation.

Investors

Similar Companies